So I'm seeing 214,560 trades and a current price of $1.87 Cdn on the TSX. Good to see. I'm assuming it might be motivated by someone(s) waiting for the financing barrier to be removed or perhaps the confirmation that things are moving ahead.

As I have said and others have recently stated there has been  nothing but positive science at RVX with apabetalone ever since June of 2013 and, in fact, for many years before that (BoM, renal,retinal, rare MD, HIV, Alheimers,etc)

So from my perspective I believe the next hurdle is the futility analysis and from my recall we have not heard much on that lately with the exception that a larger sample size is required. If there is an LOI from someone other that Hepalink, unless they will provide funding at a very low share price (equal or less than the Hepa funding) I do not think they will do a deal until the FA passes (just my hunch). And then, if the FA passes, it is my hope that the price a new partner will pay will reflect the new propbability of BoM success. And who is to say there is only one bidder. One thing for sure RVX is being very quite if something concrete is happening.

So just for fun if I assume that the USA will be the largest market for apabetalone (which is not necessarily true since the EU is a larger economy) then wouldn't it be interesting if a new partner came in and had a bidding war with Hepalink for the USA territory? Just a thought.

Anyway, it is all good news and passing the FA I believe will begin to really fuel scientific and business interest. Time to kick back and watch events unfold.

Cheers and GLTA

Toinv